US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 21:03:44 Source:politicsViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Baby Reindeer's real
Next:Eleanor Tomlinson puts on a leggy display in sparkly black minidress as she joins co
You may also like
- It's no wonder parents are taking their children on holiday during term time! Sky
- Waymo is latest company under investigation for autonomous or partially automated technology
- Golden State's WNBA expansion franchise to be known as the Valkyries
- Tiffany Haddish reveals if she's bothered by ex
- Mohammad Mokhber: Who is Iran’s acting president?
- Survey finds 8,000 women a month got abortion pills despite their states' bans or restrictions
- Susan Sarandon, 77, looks effortlessly chic in navy silk co
- Risks of handcuffing someone facedown long known; people die when police training fails to keep up
- The 13 style rules that every midlife woman MUST follow (and yes, beige really is banned!)